MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours

Phase 1
Completed
Conditions
Tumors
Interventions
First Posted Date
2014-07-08
Last Posted Date
2014-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
50
Registration Number
NCT02182206

Safety and Relative Bioavailability of BIBF 1120 Soft Gelatine Capsules Charge 1, BIBF 1120 Soft Gelatine Capsules Charge 2 and BIBF 1120 Drinking Solution in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BIBF 1120 drinking solution
Drug: BIBF 1120 capsules charge 2
Drug: BIBF 1120 capsules charge 1
First Posted Date
2014-07-08
Last Posted Date
2014-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
54
Registration Number
NCT02182193

Single Rising Oral Doses of BI 10773 in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 10773 - single rising dose
Drug: Placebo
First Posted Date
2014-07-08
Last Posted Date
2014-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
48
Registration Number
NCT02182453

WAL 801 CL Dry Syrup in Paediatric Atopic Dermatitis Patients

Phase 3
Completed
Conditions
Dermatitis, Atopic
Interventions
Drug: WAL 801 CL Dry Syrup
Drug: WAL 801 CL Dry Syrup placebo
First Posted Date
2014-07-08
Last Posted Date
2014-07-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
162
Registration Number
NCT02182557

A Study to Investigate the Procoagulant Effect of Tenecteplase (TNK-tPA), Alteplase (Rt-PA) and Streptokinase (SK) Administered to Patients With Acute Myocardial Infarction (AMI)

Phase 3
Completed
Conditions
Myocardial Infarction
Interventions
First Posted Date
2014-07-08
Last Posted Date
2014-07-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
49
Registration Number
NCT02182011

Study to Investigate the Relative Bioavailability of Ibuprofen in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
36
Registration Number
NCT02183012

The Ability of Songha Night ® to Improve Sleep in Patients With Mild to Moderate Sleep Disturbances

Phase 3
Completed
Conditions
Sleep Initiation and Maintenance Disorders
Interventions
Drug: Songha Night ®
Drug: Placebo
First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
146
Registration Number
NCT02183714

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

Phase 3
Completed
Conditions
Diabetes Mellitus, Type 2
Hypertension
Interventions
Drug: placebo
First Posted Date
2014-07-08
Last Posted Date
2018-07-31
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
166
Registration Number
NCT02182830
Locations
🇺🇸

Atlanta Clinical Research Centers, Atlanta, Georgia, United States

🇺🇸

Albert F. Johary MD, PC, Dunwoody, Georgia, United States

🇺🇸

University of Chicago, Chicago, Illinois, United States

and more 86 locations

Efficacy and Safety of Meloxicam vs. Naproxen Sodium in Patients With Acute Non Bacterial Pharyngitis or Pharyngo-tonsillitis

First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
390
Registration Number
NCT02183038

Observational Study of Meloxicam in Any Labeled Indication

Completed
Conditions
Arthritis, Rheumatoid
Interventions
First Posted Date
2014-07-08
Last Posted Date
2014-10-29
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
13039
Registration Number
NCT02182739
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy